Chief Executive Officer
Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health. Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies. As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr. Whitehead holds a BA with honours from Oxford University.
May 17, 1976 – September 1, 2022
Todd Suscovich, PhD.
Chief Technical Officer
Dr. Todd Suscovich, Chief Technical Officer, leads the implementation and further development of the Systems Serology platform at SeromYx, expanding the use of this technology beyond the Infectious Disease space. Prior to joining SeromYx, his research broadly focused on how molecular events affect both the induction and regulation of the immune response during autoimmunity and infection and how these various pathways and underlying mechanisms can be manipulated to prevent/treat infection and disease. Since 2012, he has worked closely with Dr. Alter, leading the development and optimization of the Systems Serology platform, using this technology to identify antibody features and functions that are associated with protection from HIV infection. Recognizing the broad applicability of this platform in identifying correlates of protection in infection and vaccination beyond HIV, he spearheaded the adaptation and utilization of the Systems Serology technology across a broad range of globally relevant pathogens and diseases including tuberculosis, malaria, RSV, Ebola virus, Zika virus, and pertussis. Todd holds a Bachelor of Science in Molecular Biology from the University of Pittsburgh and a doctorate in Virology from Harvard Medical School.
Lenny Moise, PhD
Dr. Lenny Moise, VP Research, manages client projects and scientific development of the SeromYx Systems Serology platform for clinical research and drug discovery in infectious disease, immuno-oncology, autoimmunity and neurology. Prior to joining SeromYx, Lenny was Director of Vaccine Research at EpiVax, where he used immunoinformatic approaches to design and develop vaccines that exploit T cell immunity for viral and bacterial infectious diseases and cancer and to screen and de-risk biologic immunogenicity. Over that time, he studied T cell responses to vaccines and developed immunoinformatic tools as a member of the faculty of the Institute for Immunology and Informatics at the University of Rhode Island and the Center for Vaccines and Immunology at the University of Georgia. Lenny trained in structure-function analysis of snake toxin-ion channel interactions using structural, biochemical, and electrophysiological methods and holds a Bachelor of Science with honors and a doctorate from Brown University.
Director of Operations
Briana Dougherty, Director of Operations, oversees multiple areas at SeromYx including Facilities, Ordering and Procurement, Quality and IT. In this role, she has implemented many internal processes and procedures and led SeromYx’s GCLP accreditation process. Prior to joining SeromYx, Briana has spent over 10 years working at multiple CAP/CLIA certified molecular diagnostic testing companies in laboratory operations and quality control. Initially starting out as a laboratory technologist, Briana spent over 5 years in quality control before moving into laboratory operations and facility management. Briana holds a B.S. with honors in Biotechnology from Worcester Polytechnic Institute.